Valcyte (valganciclovir) is indicated for:
- Treatment of Cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
- Prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk.
- Prevention of CMV disease in kidney or heart transplant patients at high risk.
To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.
FDA Drug Safety Podcast for Healthcare Professionals: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients[ARCHIVED]
FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients
FDA issues new dosing guide for children using Valcyte[ARCHIVED]
9/15/2010 - FDA Note To Correspondents